Episode
Eli Lilly Is Up 2x This Year And That’s Just the Beginning
- Podcast
- Milk Road Stocks
- Published
- Jul 3, 2026
- Duration seconds
- 2620
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/milk-road-ai-7580602/episodes/eli-lilly-is-up-2x-this-year-and-that-s-just-the-beginning/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/milk-road-ai-7580602/eli-lilly-is-up-2x-this-year-and-that-s-just-the-beginning.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
🎯 We called Micron (217%), Credo (191%), Nebius (146%), and Bloom Energy (130%) before their big runs. Want to see what we’re buying next? Come join us for just $1. ~~~~~ In this episode, we break down why Eli Lilly could become one of the biggest beneficiaries of artificial intelligence. While most investors know the company for its blockbuster GLP-1 weight-loss and diabetes drugs, the real opportunity may lie in how AI transforms drug discovery, clinical trials, manufacturing, and healthcare at scale. ~~~~~ 🚀 Real liquidity, real dividends, and just 0.04% fees- check out Bitget Stocks 2.0 ~~~~~ ✊ Follow Milk Road on Social Media: 👉 Twitter: https://x.com/MilkRoadAI 👉 YouTube: https://www.youtube.com/@MilkRoadAI 👉 Spotify: https://link.milkroad.com/spotify-mr-ai 👉 Apple Podcast: https://link.milkroad.com/applepod-mr-ai ~~~~~ 🎙 GUEST INFO 🎙 Vincent: https://x.com/WhiteCollarExit 📃 Disclaimer 📃 The information presented in this video is for educational and informational purposes only. It should not be considered as financial, legal, or tax advice. The speakers are not licensed financial advisors or registered investment advisors. Investing in cryptocurrencies carries significant risks, including the potential for substantial losses. The speakers d…